Released Feb 22, 2018, after the close
10-K filed Feb 22, 2018, 53 days after period end · 0001558370-18-000927
Q4 2017 · 10-K
Revenue$94.21M$94.21M +7.7% vs Q4 2016+8.5% vs Q3 2017
Net Income$12.09M$12.09M N/M vs Q4 2016N/M vs Q3 2017
EPS Diluted$0.08$0.08 N/M vs Q4 2016N/M vs Q3 2017
Operating Incomederived$84,787,000N/M
Operating Cash Flowderived-$9,214,000N/M
Free Cash Flowderived-$8,808,000N/M
Margins · derived
Operating margin90.0%+97.2 pt vs Q4 2016
Net margin12.8%+28.3 pt vs Q4 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2017 | Q4 2016 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue | $94.21M | $87.46M | $53.31M | $38.07M |
| Net Income | $12.09M | -$13.51M | — | — |
| EPS Diluted | $0.08 | -$0.09 | -$0.09 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR